Related Experiment Videos
TFX immunotherapy in children with ALL during remission
Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1985
Summary
Thymus factor X (TFX) immunotherapy improved immune function in children with acute lymphoblastic leukemia (ALL). TFX therapy enhanced E-rosetting capacity, T-cell numbers, and skin test reactivity, leading to fewer infections and longer remissions.
Area of Science:
- Immunology
- Pediatric Oncology
Background:
- Acute lymphoblastic leukemia (ALL) in children often compromises immune function.
- Restoring immunocompetence is crucial for managing infections and maintaining remission in pediatric ALL patients.
Purpose of the Study:
- To evaluate the in vivo and in vitro effects of thymus factor X (TFX) on immune parameters in children with ALL.
- To assess TFX's impact on infection rates and remission stability.
Main Methods:
- Assessed E-rosetting capacity, absolute lymphocyte and T-cell counts, and skin test reactivity to recall antigens in 20 children with ALL.
- Administered TFX immunotherapy and measured changes in immune markers, infection episodes, and remission status.
Main Results:
- TFX therapy significantly increased E-rosette percentages (50% to 64%) and T-cell numbers, though not to levels seen in healthy children.
- Positive skin test reactivity to recall antigens rose from 13% to 32% post-TFX treatment.
- Immunotherapy with TFX appeared to reduce infectious episodes and help stabilize remission in ALL patients.
Conclusions:
- Thymus factor X (TFX) demonstrates potential in restoring immunocompetence in children with ALL.
- In vivo TFX administration may decrease infection incidence and prolong remission duration in pediatric ALL patients.
- Further research into TFX as an immunotherapeutic agent for ALL is warranted.